EP3317402A1 - Lebensfähige zellpopulation, verfahren zur herstellung und verwendungen davon - Google Patents
Lebensfähige zellpopulation, verfahren zur herstellung und verwendungen davonInfo
- Publication number
- EP3317402A1 EP3317402A1 EP16741685.8A EP16741685A EP3317402A1 EP 3317402 A1 EP3317402 A1 EP 3317402A1 EP 16741685 A EP16741685 A EP 16741685A EP 3317402 A1 EP3317402 A1 EP 3317402A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- sialidase
- antigen
- cell population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 344
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 325
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 325
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 238
- 239000000427 antigen Substances 0.000 claims abstract description 215
- 108091007433 antigens Proteins 0.000 claims abstract description 212
- 102000036639 antigens Human genes 0.000 claims abstract description 212
- 238000011282 treatment Methods 0.000 claims abstract description 148
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 50
- 230000035800 maturation Effects 0.000 claims abstract description 45
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 230000003612 virological effect Effects 0.000 claims abstract description 15
- 208000026278 immune system disease Diseases 0.000 claims abstract description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 8
- 208000036142 Viral infection Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 125000005629 sialic acid group Chemical group 0.000 claims description 54
- 210000001616 monocyte Anatomy 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 18
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 18
- 238000011068 loading method Methods 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 17
- 210000005259 peripheral blood Anatomy 0.000 claims description 17
- 239000011886 peripheral blood Substances 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 9
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 8
- 241000701806 Human papillomavirus Species 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 2
- 102000000763 Survivin Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102100032743 Septin-4 Human genes 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract description 22
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract description 22
- 230000003614 tolerogenic effect Effects 0.000 abstract description 10
- 230000030741 antigen processing and presentation Effects 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 6
- 229940030156 cell vaccine Drugs 0.000 abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 220
- 210000004881 tumor cell Anatomy 0.000 description 129
- 102000004127 Cytokines Human genes 0.000 description 55
- 108090000695 Cytokines Proteins 0.000 description 55
- 108010058846 Ovalbumin Proteins 0.000 description 54
- 229940092253 ovalbumin Drugs 0.000 description 52
- 230000028327 secretion Effects 0.000 description 46
- 230000001965 increasing effect Effects 0.000 description 43
- 238000000684 flow cytometry Methods 0.000 description 34
- 108010074328 Interferon-gamma Proteins 0.000 description 33
- 230000007423 decrease Effects 0.000 description 30
- 210000004700 fetal blood Anatomy 0.000 description 30
- 102100037850 Interferon gamma Human genes 0.000 description 29
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 28
- 102100040247 Tumor necrosis factor Human genes 0.000 description 28
- 238000003556 assay Methods 0.000 description 27
- 108090001090 Lectins Proteins 0.000 description 25
- 102000004856 Lectins Human genes 0.000 description 25
- 241001529936 Murinae Species 0.000 description 25
- 239000002523 lectin Substances 0.000 description 25
- 230000035755 proliferation Effects 0.000 description 23
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 22
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 22
- 239000005090 green fluorescent protein Substances 0.000 description 22
- 239000013592 cell lysate Substances 0.000 description 21
- 238000003501 co-culture Methods 0.000 description 21
- 230000001976 improved effect Effects 0.000 description 21
- 210000004988 splenocyte Anatomy 0.000 description 20
- 102000003814 Interleukin-10 Human genes 0.000 description 19
- 108090000174 Interleukin-10 Proteins 0.000 description 19
- 239000006166 lysate Substances 0.000 description 19
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 18
- 230000003833 cell viability Effects 0.000 description 18
- 230000003247 decreasing effect Effects 0.000 description 18
- 102000013462 Interleukin-12 Human genes 0.000 description 17
- 108010065805 Interleukin-12 Proteins 0.000 description 17
- 102000004889 Interleukin-6 Human genes 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 17
- 108091054437 MHC class I family Proteins 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 17
- 238000010186 staining Methods 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000000770 proinflammatory effect Effects 0.000 description 15
- 102000043129 MHC class I family Human genes 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 14
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 238000007427 paired t-test Methods 0.000 description 13
- 230000002062 proliferating effect Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 11
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 11
- 230000006052 T cell proliferation Effects 0.000 description 11
- 230000006641 stabilisation Effects 0.000 description 11
- 238000011105 stabilization Methods 0.000 description 11
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 10
- 108090000672 Annexin A5 Proteins 0.000 description 10
- 102000004121 Annexin A5 Human genes 0.000 description 10
- 102210042925 HLA-A*02:01 Human genes 0.000 description 10
- 230000001472 cytotoxic effect Effects 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000012202 endocytosis Effects 0.000 description 10
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 9
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108091008048 CMVpp65 Proteins 0.000 description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 6
- 241001521394 Maackia amurensis Species 0.000 description 6
- 108010046016 Peanut Agglutinin Proteins 0.000 description 6
- 240000006028 Sambucus nigra Species 0.000 description 6
- 235000003142 Sambucus nigra Nutrition 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 235000008995 european elder Nutrition 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 125000005630 sialyl group Chemical group 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 4
- 108010075704 HLA-A Antigens Proteins 0.000 description 4
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 4
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229960000714 sipuleucel-t Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000011870 unpaired t-test Methods 0.000 description 4
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- KQNZDYYTLMIZCT-KFKPYADVSA-N (2e,7s,10e,12r,13r,15s)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\C2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KFKPYADVSA-N 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000003640 procarcinogenic effect Effects 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 108010004093 retinal S antigen peptide M Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 102210047469 A*02:01 Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010075205 OVA-8 Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 208000034615 apoptosis-related disease Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000005208 blood dendritic cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical class OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
Definitions
- the present disclosure relates to a viable cell population, suitable for cellular vaccine development.
- This viable cell population now disclosed has low sialic acid content, is loaded with specific antigens, shows higher antigen presentation, high maturation and co-stimulatory properties, and less tolerogenic properties.
- This viable cell population are used to present antigens to T cells, including antigen derived from tumours, virus or bacteria, and are capable of boosting antigen-specific T cell activity.
- the disclosure also relates to the preparation method of such viable cell population by cleaving sialic acids from living (or viable) human dendritic cell (DC) population treated with sialidase or T2 cell population treated with sialidase.
- DC human dendritic cell
- the viable cell population of the present disclosure can be used in medicine, in particular in a method for the treatment of cancer, immune diseases, or viral or bacterial infections.
- DC Dendritic cells
- DC are capable of presenting antigens to both helper (CD4 + ) and cytotoxic (CD8 + ) T cells via Major Histocompatibility Complex (MHC) class II or class I, respectively (Steinman & Cohn, 1973; Steinman & Cohn, 1974; Steinman et al., 1974).
- MHC Major Histocompatibility Complex
- DC constitute a heterogeneous blood cell population, comprising the CDllc + myeloid DC, the CD141 + myeloid DC and the CD303 + plasmacytoid DC.
- blood DC are a rare population, thus methods have been developed to differentiate blood precursor cells, such as monocytes, into DC (Sallusto & Lanzavecchia, 1994).
- Sipuleucel-T The first DC-based vaccine against cancer receiving marketing approval, was Sipuleucel-T (Provenge), developed by Dendreon Corp. (Approval Letter by Food and Drug Administration. 2010-04- 29).
- Sipuleucel-T consists in using DC from patients (autologous); obtained by differentiation of monocyte precursors in vitro and ex vivo; stimulated with a fusion protein consisting of GM-CSF and the tumour antigen, prostatic acid phosphatase (PAP).
- PAP prostatic acid phosphatase
- Sipuleucel-T has shown to be effective in patients with metastatic prostate cancer, by extending the median survival by 4.1 months and with an extended survival up to 3 years in some cases (Jahnisch et al., 2010).
- a number of other companies are developing DC-based vaccines using similar approaches, such as Geron Company with G NVAC1 and GRNVAC2 vaccines, consisting of DC expressing the telomerase gene.
- DC-based vaccines have proven to be safe and to induce anti-tumour immunological responses.
- experts in the field refer that the methods used to obtain DC-based vaccines are relatively uneasy, since they have shown limited efficacy in patients and usually require an expensive formulation.
- One of the reasons for this limited efficacy is the inefficient maturation of DC used in vaccination protocols.
- inefficient maturation may be related with aspects such as: i) insufficiency or inefficiency of the maturation stimuli used in vitro considering that, as mentioned below, at present there is no satisfying method capable of stimulating all aspects of DC maturation or ii) DC refraction to maturation stimuli, as it is the case of DCs from cancer patients due to the immunosuppressive environment induced by the tumour cells.
- DC need to undergo phenotypic and physiological changes, characterized by the up-regulation of antigen presenting MHC class I and class II molecules to present antigens (signal 1) to T cells, and co-stimulatory molecules (signal 2), such as CD86 and CD40, which promote DC interaction with T cells (Acuto et al., 2003), as well as an increased ability to secrete cytokines (signal 3).
- the expression of pro-inflammatory cytokines by DC is preferably higher than anti-inflammatory cytokines such as IL-10.
- IL-12 is actually required for in vivo antitumor activity by inducing human cytotoxic T cell activation, while IL-10 renders DCs with a tolerogenic profile.
- helper T lymphocytes are also important to assist anti-tumour immune responses. This profile can be broadly subdivided into Thl-type cytokines and Th2-type cytokines. Thl-type cytokines tend to produce pro-inflammatory responses responsible for killing tumour cells. Interferon gamma (IFN- ⁇ ) is one of the major examples of Thl cytokines.
- IFN- ⁇ Interferon gamma
- Document US20140302096A1 describes an alternative method using a composition comprising TNF-a, IL- ⁇ , PGE2, IFN- ⁇ , and TL 7/8 agonists, which increases the expression of MHC class II, co- stimulatory markers and IL-12.
- Document US20140220675 Al proposes a method to produce a population of DC capable of secreting high amounts of IL-12 and inducing the activation of cytotoxic T cells by using a combination of maturing agents comprising an array of type I interferons.
- Another related strategy (document WO2003022215 A3) refers to a specific combination of maturation factors, including the use of cytokines simultaneously with Bacillus Calmette-Guerin (BCG), which would theoretically activate intracellular DCs signaling pathways that are mediated by TLRs (Tolllike receptors).
- BCG Bacillus Calmette-Guerin
- Sialic acid refers to a large family of monosaccharides (or sugars), with nine carbons, derivatives of neuraminic acid, being the /V-acetylneuraminic acid the most common in humans. Sialic acid plays an important role in host/pathogen interaction and recognition and is a fundamental determinant for a number of immune receptors with known involvement in cellular adhesiveness and cell-to-cell interactions, such as Selectin and Siglec receptors. Sialic acid recognition occurs either on glycoconjugates of the same cell (in cis) or other cells (in trans).
- Sialic acid content depends on the expression of a set of different sialyltransferases (enzymes that transfer sialic acids) localized at Golgi or/and sialidases (enzymes that cleave sialic acid linkages) located in the cytoplasm, membrane or lysosomes. Besides this intrinsic regulation, sialic acid content is extrinsically modified by external factors, such as soluble sialyltransferases present in serum and soluble sialidases expressed by the host or pathogens.
- desialylation used in this work refers to the enzymatic removal of terminal sialic acid residues from glycoproteins or glycolipids, on a reaction catalyzed by extrinsic sialidase enzymes.
- Sialic acids are involved in many cellular functions, both in physiological and pathological processes, including the regulation of the immune system and triggering progression of certain infections and diseases (Varki, 2008; Varki & Varki, 2007). These terminal sugars can mask underlying structures, thus preventing cell-to-cell interactions through non-specific repulsive effects or by preventing recognition by other molecules such as lectins (Dall'Olio & Chiricolo, 2001; Lehmann et al., 2006; Schauer, 2009).
- Crespo H. et al. described that the inactivation of the sialyltransferases ST3Gal.l and ST6Gal.l caused a more mature phenotype in murine DC (Crespo et al., 2009).
- Cabral et al. demonstrated that desialylation strongly stimulates human monocyte derived-DC maturation and the production of several cytokines, including IL-10, via the translocation of NF- ⁇ transcription factor to the nucleus (Cabral et al., 2013).
- sialidase inhibitors which abrogates the activity of sialidase on cells surface glycans is described in some documents for viral infection therapy (document WO 2011081083 Al) and to improve platelet storage (document CN 103702556 A).
- DC-based vaccines are limited in inducing effective responses, due to their low capacity to present antigens, low co- stimulation and low cytokine expression.
- the present disclosure provides a method for stimulating all aspects of DC maturation: 1) higher antigen presentation through MHC class I and class II, 2) increased expression of co- stimulatory molecules and 3) the secretion of Thl cytokines.
- the present disclosure describes a protocol using an enzymatic (sialidase) treatment which unexpectedly improves the antigen presentation through M HC class I and class II, including the cross presentation of antigens. Higher antigen presentation, through either MHC maximizes the efficiency of DCs as antigen presenting cells, thus reducing the dosage required for vaccination.
- the disclosure also improves the expression of co-stimulatory molecules, important for efficient stimulation of T cells.
- pro-inflammatory cytokines and an unexpected decrease in the expression of anti-inflammatory cytokines, such as IL-10, benefiting anti-tumour immune responses.
- this disclosure is better than the ones described above because it improves simultaneously the expression of signal 1, 2 and 3.
- the present disclosure can be applied before or even after phagocytosis of antigen, in contrast to other inventions that can only be applied after antigen upload. This is an advantage that allows maturing DC prior to the antigen upload, thus minimizing the problem of immune suppression posed by tumour antigens that, when given to DC abrogate its maturation (i.e. are tolerogenic).
- the sialidase treatment does not affect the uptake of tumour antigens, which may be due to the fact that tumour antigens are internalized by several endocytic routes, due to their complex composition.
- the fact that sialidase treatment does not affect phagocytosis of tumour antigens presents an advantage compared to other maturation strategies that abrogate antigen internalization and thus have to be performed after upload of antigens. This disclosure thus allows maturing DC prior to the antigen upload, thus minimizing the problem of immune suppression, posed by tolerogenic tumour antigens.
- IL-10 insulin receptor kinase
- the production of IL-10 was reduced in 50% in DC treated with sialidase and uploaded with tumour antigens, compared to untouched DC, suggesting that other signaling pathways are also activated.
- Decreased IL-10 expression is an advantage since IL-10 is a Th2 cytokine that contributes to immune tolerance.
- IL-10 stimulates tumour cell proliferation and inhibits cell apoptosis.
- the present disclosure relates to a viable cell population wherein the population of viable cells is obtainable by the maturation of the dendritic cells or T2 cells with sialidase during 45 minutes to overnight, in particular 45 minutes to 16 hours at 37 °C and wherein the sialidase concentration vary between 0.002 U/mL - 0.005 U/mL per lxlO 6 of dendritic cells or T2 cells.
- M HC class II molecules is up to 1.7 or 1.8 fold higher
- the stability of M HC class I on cell surface, in particular on the DC cell surface is up to 52% higher, preferably up to 100% higher, more preferably 146% higher,
- co-stimulatory molecules is 1.3 to 1.5 fold increased, in particular the expression of the co-stimulatory molecules CD80 and CD86 is increased 1.2 and 1.1-fold, respectively;
- the secretion of pro-inflammatory cytokines is up to 1.8 fold increased, in particular is increased up to 2.5 fold, more particularly the secretion of the pro-inflammatory cytokine IL-12 is increased up to 2.5-fold; the secretion of anti-inflammatory cytokines is 1.4 to 1.9 fold decreased, in particular the secretion of anti-inflammatory cytokine IL-10 is 1.4- fold decreased; and
- the viable cell population now disclosed may comprise up to 50% of sialic acids on a cell surface of a cell treated with sialidase/sialic acids on a cell surface of a cell non-treated with sialidase, preferably 40% of sialic acids on a cell surface of a cell treated with sialidase/sialic acids on a cell surface of a cell non-treated with sialidase, more preferably up to 30% of sialic acids on a cell surface of a cell treated with sialidase/sialic acids on a cell surface of a cell non-treated with sialidase, even more preferably up to 20% of sialic acids on a cell surface of a cell treated with sialidase/sialic acids on a cell surface of a cell non-treated with sialidase.
- the sialic acids on the cell surface of the DCs or T2 cells may be: a2,3-sialiac acid and a2,6-sialic acid.
- the sialic acids on the cell surface of the DCs or T2 cells may be: a2,3-sialiac acid, a2,6-sialic acid and a2,8-sialic acid.
- the previous values are given as a ratio of a cell population treated with sialidase versus a cell population non-treated with sialidase.
- the assay for determining the percentage of sialic acids present on a cell surface was conducted using lectins, which recognize and bind to sialic acids.
- the Sambucus nigra lectin (SNA), a lectin that recognizes mainly sialic acid a2,6-linked to lactosamine (6' sialyl Gal 1,4-GlcNAc), and Maackia amurensis lectin (MAA), a lectin that recognizes mainly sialic acid a2,3-linked to lactosamine (3' sialyl Gal 1,4-GlcNAc) or, linked to the Gal 1,3-GalNAc dissacharide (Figure 2A).
- SNA Sambucus nigra lectin
- MAA Maackia amurensis lectin
- the cell viability after sialidase treatment was analised and the DCs maintain an average of 94.2 ⁇ 2.7% viability as assessed by staining with 7AAD (for dead cell exclusion) and annexin V (for apoptotic cell exclusion) (FigurelO).
- the expression of MHC class I molecules may be up to 2.3-fold higher versus a population of viable cells with 100% of sialic acids on a cell surface of a cell treated with sialidase/sialic acids on a cell surface of a cell non-treated with sialidase of the plurality of sialic acids.
- the expression of M HC class I molecules may be up to 1.7-fold higher versus a population of viable cells with 100% of sialic acids on a cell surface of a cell treated with sialidase/sialic acids on a cell surface of a cell non-treated with sialidase of the plurality of sialic acids.
- the viable cell population may further comprise an antigen, in particular a tumour antigen, a bacterial antigen and a viral antigens, wherein said antigen is at the cell surface or is internalized.
- the tumour antigen may be selected from the following list: a peptide, a protein, a whole cell antigen, wherein the whole cell antigen may be a lysate of the tumour cells.
- the tumour antigen may be selected from the following list: gastric carcinoma antigen, cancer type-specific tumour associated antigens, preferably carcinoembryonic antigen (CEA), mucin (MUC), prostate-specific membrane antigen (PSMA), melanoma antigen, gplOO, BRCA and ras and/or a universal tumour associated antigen selected from the group of Survivin and TERT, or mixtures thereof.
- gastric carcinoma antigen preferably carcinoembryonic antigen (CEA), mucin (MUC), prostate-specific membrane antigen (PSMA), melanoma antigen, gplOO, BRCA and ras and/or a universal tumour associated antigen selected from the group of Survivin and TERT, or mixtures thereof.
- CEA carcinoembryonic antigen
- MUC mucin
- PSMA prostate-specific membrane antigen
- melanoma antigen gplOO, BRCA and ras
- a universal tumour associated antigen selected
- the melanoma antigen may be MART, PRAM E, BAGE 2, BAGE 3, BAGE 4, BAGE 5, BAGE 6, BAGE 7, BAGE 8, BAGE 9, BAGE 10, GAGE 1, or mixtures thereof.
- the viral antigen may be selected from the following list: the Epstein-Barr virus nuclear antigen, human papilloma virus antigen, hepatitis B antigen, hepatitis C antigen, or mixtures thereof.
- the Epstein-Barr Virus nuclear antigen may be EBNA 1, EBNA 2, EBNA 3, EBNA 4, EBNA 5, EBNA 6, or mixtures thereof.
- the human papilloma virus antigen may be human papilloma virus antigen E6, human papilloma virus antigen E7, or mixtures thereof.
- the present disclosure also relates to a viable cell population, as previously described, for use in medicine.
- the viable cell population now disclosed may be used in the treatment or prevention of cancer, immune disease, viral infectious disease or bacterial infectious disease.
- the viable cell population may be a dendritic cell population or T2 cells is isolated from blood; wherein the dendritic cell population is isolated from differentiation of monocytes or CD34 + hematopoietic stem cells, or cells from the peripheral blood.
- This disclosure also relates to a vaccine comprising the viable cell population now disclosed for use in the treatment or prevention of cancer, immune diseases, viral infections or bacterial infections.
- said vaccine may further comprises a pharmaceutically acceptable carrier.
- said vaccine may comprise an effective dosage amount is about 1 x 10 5 - 1 x 10 10 viable cells, in particular viable dendritic cells or viable T2 cells.
- the present disclosure also relates to a pharmaceutical composition comprising a viable cell population as now disclosed, in a therapeutically effect amount and a pharmaceutically acceptable excipient for use in the treatment or prevention of cancer, immune disease, viral infectious disease or bacterial infectious disease.
- the present disclosure relates to a method for production of a viable cell population as now disclosed comprising the steps of:
- the removing step of a2,3-sialic acid, and a2,6-sialic acid from a cell surface may precede the maturing step.
- this method may further comprise a step of removing of a2,8-sialic acid from the cell surface of the dendritic cell population or from the cell surface of the T2 cell population.
- this method may comprises a loading step of an antigen at the surface of the population of viable dendritic cells or at the surface of the viable T2 cells.
- the loading step of the antigen is performed at 37 Q C, 30 minutes up to 4 hours, and up to 100 ⁇ of said antigen.
- the dendritic cell population or T2 cell population is isolated from blood, from differentiation of monocytes, from CD34 + hematopoietic stem cells, or from the peripheral blood.
- the monocytes may be isolated from peripheral blood or from cord blood.
- the CD34 + hematopoietic stem cells may be isolated from cord blood or from peripheral blood.
- the maturing step is performed for 45-80 minutes a 37 Q C, preferably at 45-60 minutes at 37 Q C.
- the concentration of sialidase is 0.002 U/mL - 0.005 U/mL per lxlO 6 of dendritic cells or T2 cells.
- the sialidase enzyme may be a recombinant or purified from a biological source, in particular wherein the biological source of sialidase may be from bacterial, viral or mammalian, including human sources.
- Sialidase cleaves cell surface sialic acids.
- the cell surface sialic acid residues that are removed comprise a.2,3- and a2,6-linked sialic acids and in a lesser extent a2,8- linked sialic acids.
- FIG. 1 Human DCs are obtained by differentiation of blood precursors.
- the blood precursors were monocytes or CD34 + cells.
- Monocytes were isolated from (A) adult peripheral blood cells or from (B) cord blood cells using magnetic beads conjugated to antibodies against CD14.
- Monocytes were cultured at a concentration of 1 x 10 6 cells/ml in media supplemented with 750 U/mL of IL-4 and 1000 U/mL of GM-CSF, at 37 Q C, in a humidified atmosphere with 5% CO2.
- CD14 a marker mainly expressed by monocytes
- CDla or CDlc markers expressed by human DC and HLA-D (M HC class II) an antigen presenting molecule.
- monocytes lose their expression of CD14 and acquire significant expression of CDla or CDlc, also increasing the expression of HLA-DR.
- monocytes after five days in culture, acquire a DC phenotype, while monocytes isolated from cord blood acquire a DC phenotype after seven days.
- the differences in time for differentiation between monocytes from adult blood and cord blood are due to the cell immaturity.
- the differentiation yield is above 90%, meaning that almost every monocyte differentiates into DC.
- the figure shows representative histograms of at least three independent assays. Positive staining is represented in dark grey and isotype control is shown in light grey.
- FIG. 1 Flow cytometric analysis of DC obtained from differentiation of human monocytes (MoDC), stained with fluorescent Sambucus nigra lectin (SNA; recognizing a2,6-sialic acids), Maackia amurensis lectin (MAA; recognizing a2,3-sialic acids) and Peanut agglutinin lectin (PNA; recognizing unsialylated core 1 structures).
- SNA Sambucus nigra lectin
- MAA Maackia amurensis lectin
- PNA Peanut agglutinin lectin
- the degree of desialylation is quantified based on the ratio between the mean fluorescence intensity (MFI) ⁇ SEM of DC after sialidase treatment compared to untreated DC. Data shows that sialidase treatment leads to a 50 ⁇ 26 % and a 45 ⁇ 10 % decrease in SNA and MAA staining, respectively, while PNA staining increases 70 ⁇ 13 fold. Statistical significance was determined using a two-tailed paired t-test (*P ⁇ 0.05 or ***P ⁇ 0.0001) and refers to the difference between untreated and sialidase treated MoDC (n>3) (B) Sialidase treatment does not affect the capacity of DC to endocytose tumour cell lysates.
- MFI mean fluorescence intensity
- DC previously treated or not with sialidase were incubated with fluorescent tumour cell lysates, for 3 hours at 37 Q C (condition that favours endocytosis) and 4 Q C (condition where endocytosis is inhibited), and analysed by flow cytometry.
- the capacity for endocytosis was quantified based on the number of DC which showed significant increase in the M Fl, after endocytosis experiments at 37 Q C. Increased MFI means that cells have internalized fluorescent antigens.
- the values obtained in assays conducted at 4 Q C which could evaluate the occurrence of eventual unspecific binding to cell surface, showed negligible fluorescence. Data showed that there are no significant differences between assays conducted with DC not treated (left graph) or treated with sialidase (right graph).
- FIG. 3 Desialylated human MoDC loaded with whole tumour cell antigens express a more mature profile and have higher secretion of pro-inflammatory cytokines.
- MoDC were first treated with sialidase (Sia), for 1 hour at 37 Q C or left untreated, followed by loading with lysates of the tumour cell line MCF-7 (TL), as a source of whole tumour cell antigens, as described in Example 5.
- Control experiments with non-sialidase treated and unloaded MoDC were run in parallel (represented in the figure as MoDC).
- A Flow cytometric analysis of the expression of antigen presenting molecule HLA-DR (M HC class II), and co-stimulatory molecule CD86.
- Untreated and unloaded MoDC have the lowest HLA-DR and CD86 expression, namely 61082 ⁇ 13341 and 5749 ⁇ 912.4 of mean fluorescence intensity (M FI), respectively.
- M FI mean fluorescence intensity
- IL- 10 The expression of IL- 10 was 79.50 ⁇ 44.02 pg/mL in MoDC TL and 56.44 ⁇ 49.44 pg/mL in MoDC Sia+TL .
- the sialidase treatment decreased 1.4-fold the IL-10 secretion.
- the IL-6 and TNF-a expression was not significantly altered after sialidase treatment, showing that there is not excessive pro-inflammatory cytokines release after sialidase treatment.
- Graph values represent the mean concentration (pg/mL) ⁇ SEM of at least three independent assays. Statistically significant differences were calculated using a two-tailed paired t-test (*P ⁇ 0.05).
- FIG. 4 Sialidase treatment of human MoDC loaded with whole tumour cell antigens induces T cell activation.
- MoDC were first treated with sialidase (Sia), for 1 hour at 37 Q C or left untreated, followed by loading with lysates of the tumour cell line MCF-7 (TL), as source of whole tumour cell antigens, as described in Example 5.
- MoDC were then used in co-cultures with autologous T cells for 4-8 days in the presence of low-dose IL-2.
- A Induction of T cell proliferation by MoDC. T cells were previously labeled with CFSE and the progeny, i.e., the percentage of T cells that proliferated was estimated by flow cytometry, based on the dilution of CFSE.
- the histograms show representative experiments with T cells that were co-cultured with: unloaded MoDC (panel d), with MoDC loaded with tumour cell line MCF-7 lysates, as source of whole cell antigen (panel e) or with sialidase treated MoDC loaded with MCF-7 cell line lysates (panel f).
- Unstimulated T cells panel c) served as a negative control and phytohaemagglutinin- stimulated T cells (panel b) as a positive control. In panel a, it is represented the parental population (dark grey) and the unstained control (light grey).
- MoDC loaded with tumour cell lysates resulted in 41.3 ⁇ 14 % of proliferative T cells, a 4.9-fold increase when compared to T cells in culture alone (9.5 ⁇ 0.8 %), and a 1.5-fold increase when compared to T cell in culture with MoDC (27.0 ⁇ 5.9 %).
- T cell boosted by MoDC expressed 200.1 ⁇ 162.0 pg/mL of TNF-a, which is 1.9-fold more than T cell alone.
- MoDC TL or MoDC Sia+TL the TNF-a secretion increases to 241.9 ⁇ 139.4 and 514.6 ⁇ 246.0 pg/mL, respectively.
- sialidase treatment prior to the upload of DC with tumour antigen improves 2.5-fold the ability of autologous T cells to secrete TNF-a.
- T cells boosted by Mo-DC secreted 7643.6 ⁇ 3019.6 pg/mL, which is 3.4-fold more than T cells alone.
- CD3 + T cells were co-cultured with MCF-7 cells in a ratio of 1 tumour cells: 10 T cells; non-stimulated T cells were cultured with MCF-7 as control. Cells were co-cultured for 5 hour, after which, the degranulation of cytotoxic T cells against tumour cells was determined by the percentage of cells expressing the CD107a marker. The fact of co-culturing tumour cells with unstimulated T cells, led to the degranulation of 2.62 ⁇ 1.49 % of the T cells.
- T cells that had been previously stimulated with MoDC the percentage of cytotoxic T cells that had degranulated, when in contact with tumour cells increased to 9.84 ⁇ 1.15 % (3.8-fold increase); when using T cells stimulated with MoDC TL , it increased to 15.55 ⁇ 1.4 %, (5.9- fold increase), and the highest increase (7-fold increase) was achieved when using T cells stimulated with MoDC Sia+TL , leading to the degranulation of 18.29 ⁇ 3.46 % of the T cells.
- T cells boosted with DC that were sialidase treated prior to the upload with tumour antigens show 18% better ability to kill tumour cells than those that were boosted with DC loaded with antigens only.
- Graph values represent the percentage ⁇ SEM of CD107a + T cells of at least four independent assays. Statistically significant differences were calculated using a two-tailed paired t-test (**P ⁇ 0.001 and ***P ⁇ 0.0001).
- B Survival of tumour cells co-cultured with T cells.
- GFP green fluorescent protein
- tumour cells in co-culture alone have a percentage of survival superior than 94%.
- the survival of the tumour cell decreases to 77.53 ⁇ 7.77 %, and it still further decreases to 66.50 ⁇ 5.73 % when T cells had been stimulated with MoDC Sia+TL .
- T cells boosted with MoDC that were sialidase treated previously to the upload with tumour antigen show 17% better ability to reduce tumour cell survival than those that were boosted with MoDC only loaded with tumour antigens.
- Graph values represent the percentage ⁇ SEM of viable tumour cells (GFP + ) of four independent assays. Statistically significant differences were calculated using a one-tailed paired t-test (*P ⁇ 0.05).
- the secretion of IFN- ⁇ cytokine was measured by ELISA, as a measure to evaluate the activation of CD8 + T cell clones. Results were normalized to the IFN- ⁇ levels of the incubation of T cells with MoDC loaded with the short peptide, without sialidase treatment and refer to the secretion ⁇ SEM of IN F- ⁇ for three independent experiments. With the short peptide (positive control), using sialidase treated MoDC, the expression of I FN-Y increased 49%, relatively to the condition with untreated MoDC. When no peptide was used ( ⁇ ; negative control), the secretion of IFN- ⁇ was almost inexistent, dropping to 4% and 2% (96% and 98% decrease), for untreated and sialidase treated MoDC, respectively.
- gplOO peptide bound MHC-I is more stable on sialidase treated T2 cells.
- T2 binding assays were performed by incubating cells, treated or not with sialidase, with different concentrations of gplOO short peptide in the presence of ⁇ -microglobulin for 3 to 4 hours at 37 °C. After incubation, T2 cells were washed and stained with anti-HLA-A*02 antibody, and analysed by flow cytometry. Expression of HLA at cell surface was used a measure to evaluate M HC stabilization.
- FIG. 7 Sialidase treatment improves maturation of murine DC and presentation of the ovalbumin model antigen.
- A Sialidase treatment of splenic DC removes a2,6- and a2,3-linked sialic acids.
- Murine splenic DC were treated with sialidase (DC sia ; black bars) or left untreated (DC; white bars), stained with Sambucus nigra lectin (SNA; recognizing a2,6-sialic acids), Maackia amurensis lectin (MAA; recognizing a2,3-sialic acids) and Peanut agglutinin lectin (PNA; recognizing unsialylated core 1 structures) and analysed by flow cytometry.
- SNA Sambucus nigra lectin
- MAA Maackia amurensis lectin
- PNA Peanut agglutinin lectin
- M FI mean fluorescence intensity
- B Evaluation of maturation and co-stimulatory markers after sialidase treatment.
- Murine DC were treated with sialidase (grey bars) or left untreated (white bars) and the maturation markers were evaluated by flow cytometry. Comparing untreated and sialidase treated DC, the M HC class II (IA B ) increased (15.3 ⁇ 0.5 vs. 18.9 ⁇ 0.7 MFI, *P ⁇ 0.05), as well as MHC class I (H-2K b ) (236.8 ⁇ 1.6 vs.
- FIG. 8 Sialidase treatment of murine DC enhances their ability to activate ovalbumin specific T cells against ovalbumin expressing tumour cells.
- Murine splenic DC were pulsed with OVA for 4 hours and treated or not with sialidase for 1 hour.
- Splenocytes from OT-I or/and OT-II mice were isolated and co- cultured with DC for 72 hours in a ratio of 1:2 (DC: splenocytes).
- OT-II T cell sialidase treated OVA-loaded DC (+OVA+sia) significantly increase the proliferation of OVA-specific CD4 + T cell, compared with untreated OVA-loaded DC (+OVA-sia) (50.68 ⁇ 3.50 vs 30.43 ⁇ 7.33 % CFSE low cells, *P ⁇ 0.05).
- sialidase treatment of murine DCs improved their ability to induce the proliferation of: OT-I in 9%, and of OT-II in 66%.
- Graphs show the values of mean percentage ⁇ SEM of CFSE low cells.
- the TNF-a production was significantly up-regulated in the co-culture of OT-II splenocytes plus sialidase treated OVA-pulsed DC (+OVA+sia) compared to the untreated ones (+OVA-sia) (228.9 ⁇ 22.36 vs 143.5 ⁇ 25.48 pg/mL, *P ⁇ 0.05).
- the production of IL-6 (170.7 ⁇ 26.46 vs 67.24 ⁇ 33.64 pg/mL, *P ⁇ 0.05) and IFN- ⁇ (734.0 ⁇ 86.45 vs 370.6 ⁇ 102.7 pg/mL, *P ⁇ 0.05) was also significantly upregulated.
- sialidase treatment of murine DCs improves the ability of CD4 T cells to produce 1.6- fold more TNF-a, 2.60-fold more IL-6 and 1.98-fold more IFN- ⁇ .
- a tendency of a higher production of TNF- ⁇ and IFN-y secretion was observed after OT-I plus OT-II cells were co-cultured together with sialidase treated OVA-pulsed DC compared with untreated ones.
- Graphs show the mean ⁇ SEM of cytokine concentration (pg/mL) for at least 3 independent assays. Statistical significance was determined using a two-tailed paired t-test.
- C Induction of cytolysis on tumour targets was investigated by culturing untreated (untreated; black bars) or sialidase treated (sialidase treated; grey bars) OVA-pulsed DC, splenocytes from either OT-I or OT-II mice or both and OVA-expressing B16 mouse melanoma cells (B16- OVA) for 24 hours.
- B16-OVA tumour cell death was assessed by staining with 7-ADD and annexin-V and analysed by flow cytometry.
- Sialidase treated OVA-pulsed DC induced a higher B16-OVA cell cytotoxicity compared to untreated ones.
- Graphs show the values of mean percentage ⁇ SEM of viable cells of two independent assays.
- Statistical significance (*P ⁇ 0.05 or **P ⁇ 0.001) refers to the difference between untreated and sialidase treated DC and was calculated using a two-tailed paired t-test.
- FIG. 9 Sialidase treatment of murine sDCs loaded with OVA improves T cell cytotoxicity against tumour cells. Induction of cytolysis of tumour targets was tested by co-culturing untreated (light grey bars) or sialidase treated (black bars) OVA-pulsed sDCs and splenocytes from either OT-II or OT-I mice for 72 hours. After, primed T cells and OVA-expressing B16 mouse melanoma cells (B16-OVA) were co- cultured for 24 hours. B16-OVA tumour cell death was assessed by staining with 7-AAD and annexin-V and analysed by flow cytometry.
- OT-I I cells that were pulsed with sialidase treated sDCs induced a higher tumour cell cytotoxicity compared to those pulsed with fully sialylated sDCs (55.68 ⁇ 5.7 vs. 37.79 ⁇ 4.5, 1.5-fold).
- B OT-I cells that were pulsed with sialidase treated sDCs induced a higher tumour cell cytotoxicity compared to those pulsed with fully sialylated sDCs (52.59 ⁇ 7.9 vs. 37.86 ⁇ 3.0, 1.4-fold).
- Sialidase treatment improved 1.7-fold the reactivity of 25-D1.16 antibody, demonstrating higher presentation of the SI IN FEKL peptide through M HC class I.
- Graphs show the M FI ⁇ SEM of two independent assays.
- Statistical significance (** P ⁇ 0.001) refers to the difference between untreated and sialidase treated DCs and it was determined using a two-tailed unpaired t-test.
- Desialylated MoDCs show higher levels of maturation markers and expression of Thl inducing cytokines.
- A Desialylated MoDCs show a higher maturation phenotype than fully sialylated MoDCs. The expression of several maturation markers was evaluated by flow cytometry. MoDCs were first treated with sialidase (Sia) for lh at 37 Q C and then loaded (A, right panel) or not (A, left panel) with lysates of the MCF-7 tumour cell line (TL), as a source of whole tumour cell antigens, as described in Example 5.
- Sia sialidase
- Unloaded DCs that were treated with sialidase showed a significant increase expression of the antigen-presenting molecules M HC-I and M HC-II (2.9 and 1.5-fold, respectively), and of the co-stimulatory molecules CD80 and CD86 (1.9-fold in both cases).
- a significantly improved maturation phenotype was observed after sialidase treatment of MoDCs loaded with lysates of the MCF-7 tumour cell line ; with a significant increase in the expression of M HC-I and M HC-II molecules (2.3 and 1.7-fold increase, respectively), and a slight increase of the co-stimulatory molecules CD80 and CD86 (1.2 and 1.1- fold increase, respectively).
- IL-10 The expression of IL-10 was 79.50 ⁇ 44.02 pg/mL in MoDC TL and 56.44 ⁇ 49.44 pg/mL in MoDC Sia+TL .
- sialidase treatment decreased 1.4-fold the IL-10 secretion.
- IL-6 and TNF-a expression was not significantly altered after sialidase treatment, showing that there is not an excessive pro-inflammatory cytokines release after sialidase treatment. This is recommendable in vaccination settings to avoid excessive pro-carcinogenic inflammation.
- Graph values represent the mean concentration (pg/mL) ⁇ SEM of at least three independent assays. Statistically significant differences were calculated using a two-tailed paired t-test (*P ⁇ 0.05).
- FIG. 12 Sialidase treatment of human adult or cord blood MoDCs improves their ability to activate T cells. MoDCs were first treated with sialidase (Sia), for 1 hour at 37 Q C or left untreated, followed by loading with lysates of the tumour cell line MCF-7 (TL), as source of whole tumour cell antigens, as described in Example 5. MoDCs were then used in co-cultures with autologous T cells for 4-8 days in the presence of IL-2. (A) Induction of T cell proliferation by MoDCs. T cells were previously labeled with CFSE and the progeny, i.e., the percentage of T cells that proliferated was estimated by flow cytometry, based on the dilution of CFSE.
- the histograms show representative experiments with T cells that were co- cultured with: unloaded MoDCs (panel a), with MoDCs loaded with tumour cell line MCF-7 lysates, as source of whole cell antigen (panel b) or with sialidase treated MoDCs loaded with MCF-7 cell line lysates (panel c).
- Unstimulated T cells served as a negative control and phytohaemagglutinin-stimulated T cells (panel e) as a positive control.
- MoDC TL tumour cell lysates
- T cells boosted by Mo-DCs secreted 12489 ⁇ 3067 pg/mL, which is 4.1-fold more than T cells alone.
- MoDC TL or MoDC Sia+TL the secretion of IFN- ⁇ increases to 15784 ⁇ 3360 or 20392 ⁇ 3966 pg/mL, respectively.
- sialidase treatment prior to the upload of DCs with tumour antigen improves 1.3-fold their capacity to activate the secretion of IFN- ⁇ by autologous T cells.
- T cell stimulated by MoDCs expressed 200.1 ⁇ 72.5 pg/mL of TNF-a, which is 1.9-fold more than T cell alone.
- CBMoDCs cord blood MoDCs
- Sia sialidase
- Stimulation of T cell proliferation was performed in a mixed lymphocyte reaction, where CBMoDCs were used in co-cultures with allogenic adult T cells for 7 days in the presence of IL-2.
- T cells were previously labelled with CFSE and the progeny, i.e., the percentage of T cells that proliferated was estimated by flow cytometry, based on the dilution of CFSE as described in Example 3.
- Tumour cell viability is decreased when T cells are challenged with desialylated DCs. Tumour cell viability was evaluated based on the expression of GFP in tumour cells. By measuring the expression of the GFP, in GFP-expressing tumour cells, it is possible to infer which cells are viable.
- GFP is a pH sensitive dye which fluorescence decreases significantly when the pH of the cell cytoplasm decreases, as it is the case of T cell- dependent apoptosis.
- Tumour cell viability was significantly decreased when incubated with T cells that had been previously primed with desialylated MoDCs loaded with tumour-antigens (MoDC Sia+TL ; 66.50 ⁇ 5.3 %), compared to those incubated with T cells primed with fully sialylated MoDCs (MoDC TL ; 77.53 ⁇ 7.8 %).
- Graph values represent the percentage ! SEM of viable tumour cells (GFP + ) of four independent assays.
- Tumour cell death is increased is decreased when T cells are challenged with desialylated DCs. Tumour cell loss of viability was evaluated based on the annexin V and 7-AAD staining.
- Non-stimulated T cells were cultured with MCF-7-GFP as control (data not shown).
- Graph represents the percentage ⁇ SEM of apoptotic tumour cells assessed by staining with Annexin-V and 7-AAD, in 3 independent measurements.
- Tumour cell apoptose was significantly increased when cells were incubated with T cells that had been previously primed with desialylated MoDCs loaded with tumour-antigens (MoDC Sia+TL ;37.95 ⁇ 1.83 %), compared to those incubated with T cells primed with fully sialylated MoDCs (MoDC TL ;32.03 ⁇ 2.47 %).
- T cells cytotoxic activity against tumour cells was also evaluated based on their degranulation activity (expression of the CD107a marker).
- T cells stimulated with DC that were sialidase treated prior to the upload with tumour antigens show 1.2-fold better ability to kill tumour cells than those that were stimulated with DCs loaded with antigens only
- FIG. 14 Sialidase treatment improves the ability of MoDCs to activate tumour antigen gplOO- specific T cells.
- gplOO peptide bound M HC- I is more stable on sialidase treated T2 cells.
- T2 binding assays were performed by incubating cells, treated or not with sialidase, with different concentrations of gplOO short peptide in the presence of ⁇ - microglobulin for 3 to 4 hours at 37 °C. After incubation, T2 cells were washed and stained with anti-HLA- A*02 antibodies, and analysed by flow cytometry. Expression of HLA at cell surface was used as a measure to evaluate MHC stabilization. Data were normalized to the condition without peptide (no peptide) and without sialidase treatment.
- T2 binding assays were performed by incubating cells with brefeldin A (BFA), blocking the Golgi network exporting nascent proteins to cell membrane. BFA was added and T2 cells were treated with sialidase as described before, in the presence of ⁇ -microglobulin. After 1 hour of treatment, sialidase was washed out but BFA was left in culture during the course of the experiment. At different time points, cells were stained with anti-HLA-A*02 antibodies, and analysed by flow cytometry. Data were normalized against the basal level of expression of HLA-A*02 by T2 cells. After 1 hour, T2 cells showed a 30% fold decrease in the expression of MHC-I.
- BFA brefeldin A
- sialidase treated cells were able to sustain MHC-I expression (8% increase). After 3 hours, sialidase treated cells still show a higher expression of HLA-A*02 molecules on cell surface (only 11% decreased) against 54% decrease in the condition without sialidase treatment. Graphs show the mean fluorescence intensity ⁇ SEM of 6 independent experiments. [088] Figure 15. Sialidase treatment improves maturation of murine DCs. (A) Sialidase treatment of splenic DCs removes a.2,6- and ct2,3-linked sialic acids.
- Murine splenic DC were treated with sialidase (sDC Sia ; grey bars) or left untreated (sDCs; white bars), stained with Sambucus nigra lectin (SNA; recognizing a2,6-sialic acids), Maackia amurensis lectin (MAA; recognizing a2,3-sialic acids) and Peanut agglutinin lectin (PNA; recognizing unsialylated core 1 structures) and analysed by flow cytometry. It was observed that sialidase treatment significantly decreased MAA binding (2.9-fold) and increased PNA staining (30.9-fold), resulting from the removal of a2,3-linked sialic acids.
- SNA Sambucus nigra lectin
- MAA Maackia amurensis lectin
- PNA Peanut agglutinin lectin
- FIG. 16 Sialidase treatment of murine sDCs enhances their ability to induce proliferation and activation of ovalbumin-specific CD4 + and CD8 + T cells.
- Murine splenic DCs sDCs
- Desialylated sDCs strongly induce proliferation, activation and differentiation of CD4 + T cells into a Thl effector phenotype.
- Splenocytes from OT-II were isolated and co-cultured with the sDCs for 72h in a ratio of 1:2 (sDCs: splenocytes).
- CD4 + T cells were determined using a CFSE dilution and the expression of CD69 and CD44, respectively (gating on CD4 + T cells) was evaluated.
- Flow cytometry analysis show an increased proliferation of CD4 + T cells primed with fully sialylated OVA-pulsed sDCs, when compared with untreated ones (50.68 ⁇ 3.50 vs 30.43 ⁇ 7.33 % CFSE low cells, 1.7-fold), as well an increased activation (22.77 ⁇ 1.033% vs. 16.90 ⁇ 0.4509, 1.3-fold).
- TNF-a secretion was significantly up-regulated in co-cultures of OT-II splenocytes with OVA-pulsed sDCs treated with sialidase compared to untreated ones (228.9 ⁇ 22.36 vs.
- Splenocytes from OT-I were isolated and co-cultured with sDCs for 72h in a ratio of 1:2 (sDC: splenocytes).
- the proliferation and activation of CD8 + T cells was determined by CFSE dilution and cell surface expression of CD69 and CD44 markers (gating on CD8 + T cell).
- Sialidase treatment of sDCs showed a tendency to induce a higher proliferation of CD8 + T cells compared to untreated sDCs (23.47 ⁇ 2.439 vs. 21.23 ⁇ 4.288% of CFSE low cells).
- CD8 + T cells that were treated with sialidase showed a significant expression of CD69 and CD44 markers compared to fully sialylated OVA-pulsed sDCs (10.09 ⁇ 0.2583 vs. 8.320 ⁇ 0.4136%, 1.2-fold).
- the levels of IFN- ⁇ , IL-6, and TNF-a production in the supernatants of co-cultures were evaluated by ELISA.
- Graphs show the mean ⁇ SEM of cytokine concentration (pg/mL) for at least 3 independent assays. Statistical significance was determined using a two-tailed unpaired t- test.
- the present disclosure relates to a novel DC population with low sialic acid content, shows high M HC class I expression due to higher stability of the molecule at cell surface, high maturation and co- stimulatory properties, and less tolerogenic properties, suitable for cellular vaccine development.
- These DC are loaded with specific antigens, including peptides, proteins, or whole cell antigens, in particular tumour antigens, viral antigens and/or bacterial antigens, which are presented to T cells, and are capable of boosting antigen-specific T cell activity.
- These DCs are used to present several antigens to T cells, including tumour, viral or bacterial antigens, and are capable of boosting antigen-specific T cell activity.
- This disclosure also relates to the preparation method of such a mature DC population by cleaving sialic acids from living, viable human DC with sialidase, with the purpose to improve their immune potency.
- the present disclosure also relates to the DCs generated by sialidase treatment show a decrease in the sialic acid expression, in particular a 50% decrease of the expression of a2,6 sialic acid, 45% decrease a2,3 sialic acid and to a lesser extent a decrease of the expression of a2,8 sialic acid.
- DCs show: i) improved expression of MHC class I and II molecules, in particular 2.3 and 1.7-fold increase, respectively; ii) up to 146% of higher stability of M HC class I on cell surface and improved binding of exogenously supplied high affinity peptides that can bind directly to MHC-I, without previous endocytosis and processing; iii) increased expression of co-stimulatory molecules, CD80 and CD86, in particular 1.2 and 1.1-fold increase, respectively; iv) higher secretion of pro-inflammatory cytokines, such as IL-12 with 2.5-fold increase; and 1.4-fold decreased secretion of anti-inflammatory cytokines; v) higher capacity to activate T cells with a Thl phenotype, that produces 2.1-fold more TNF-a and 1.3- fold more IFN- ⁇ and to expand 1.4-fold better the T cells; vi) 20% higher capacity to induce T cell cytotoxic activity towards tumour cells; vii) up to 1.7-fold higher antigen cross-presentation,
- the DCs are generated by sialidase treatment.
- sialidase treatment can be applied to DCs uploaded with target antigens, such as peptides, proteins, or whole cell antigens, which can be tumour antigens or other relevant antigens, such as viral and bacterial antigens.
- the treatment of DCs with this single compound, the sialidase provides all aspects of DC full maturation that are needed for effective cellular-mediated immune responses in DC- based vaccines.
- this method uses a single and defined enzyme, the sialidase, in contrast with the other protocols to prepare DC-based vaccines, which use cocktails of cytokines or bacterial antigens.
- the use of a single enzyme allows a cost-efficient method to activate DCs.
- the use of only one enzyme reduces excessive cell manipulation that leads to a significant decrease in DC viability and functionality. This is the first disclosure using an enzymatic treatment on DCs for specific therapeutic purposes.
- the present disclosure also relates to a method used for endowing immune cells with an improved capacity to induce effective responses in vaccination settings:
- a method for the production of immune cells which includes desialylation of molecules at cell surface, maintaining cell viability;
- a method for the production of desialylated immune cells such as DCs which includes treating cells with a recombinant exogenous sialidase, an enzyme that cleaves sialic acid moieties linked to glycans decorating cell surface receptors;
- the method of the present disclosure can be applied to different sources of DC, including DC derived from cord blood which are immature and tendentiously tolerogenic, due to maternal-fetal tolerance; DC differentiated from monocytes isolated from different blood sources, such as human adult peripheral blood and cord blood, or DC differentiated from CD34 + hematopoietic stem cells isolated from cord blood or other sources.
- DC derived from cord blood which are immature and tendentiously tolerogenic, due to maternal-fetal tolerance
- DC differentiated from monocytes isolated from different blood sources such as human adult peripheral blood and cord blood, or DC differentiated from CD34 + hematopoietic stem cells isolated from cord blood or other sources.
- the method of the present disclosure due to their very low toxicity on viable DC and high enzymatic activity, are useful for the ex vivo modification of glycans on the surface of DC.
- the modified DC are useful in clinical settings to achieve vaccines to be used in cancer therapeutics, also including immune diseases and infectious diseases.
- the disclosure provides the composition described above for use in therapy. Further, the present disclosure provides the composition described above for use in the treatment of cancer, immune diseases or infectious diseases.
- the present disclosure relates to a new population of DCs and to an advantageous method for obtaining it.
- Such method consists in cleaving sialic acids from the surface of living and (viable) human DC, with the purpose of inducing maturation of antigen loaded DC-, including improving DC ability to present antigens as well as boosting antigen-specific T cell activity.
- DC can be isolated directly from blood or other tissue or obtained from differentiation of cell precursors, such as monocytes or CD34 + cells.
- DC generated from differentiation of blood precursors have the advantage to allow large amounts of DC.
- the DCs may be obtained from differentiation of monocytes, these are isolated from peripheral blood (PB) withdrawn from adult individuals or from cord blood (CB), and usually 0.5 to 1 x 10 6 monocytes can be obtained per each ml of blood.
- the method to differentiate monocytes into DC is the method described by Sallusto & Lanzavecchia (1994), using IL-4 and GM-CSF cytokines, where the differentiation yields are above 70%, more particular above 90%, meaning that almost every monocyte will differentiate into DC.
- Peripheral blood can be, for example, obtained from leukapheresis from cancer patients or from blood donations, in case of healthy individuals, while CB can be obtained, for example, from a CB bank.
- the method of obtaining human DC can be as mentioned in Example 1, which includes DC obtained by differentiation of blood monocytes isolated from peripheral blood or from cord blood ( Figures 1A and IB, respectively).
- the sialidase treatment of human DC was carried out as follows: DC are submitted to an enzymatic treatment with an exogenous sialidase, that removes ⁇ 2,3-, ⁇ 2,6- and to a lesser extent a2,8- linked sialic acids.
- the sialidase can be recombinant or purified from biological sources.
- Sialidase can be from microbial, mammalian or other sources.
- DC are desialylated using a sialidase at a concentration ranging from 0.025U/mL to O.lU/mL, from 45 minutes to overnight, at 37 Q C.
- the optimal proportion ranged between 0.002U/mL to 0.005U/mL per lxlO 6 DCs.
- Sialidase treatment can be stopped by resuspending cells in complete media containing FBS or by diluting the sialidase reaction volume 10 times with culture medium.
- DCs may be desialylated using an optimal concentration of sialidase ranging from 0.002 U/mL to 0.005 U/mL per lxlO 6 DCs at 37 ⁇ C and an optimal desialytation time of 45 minutes.
- sialidase ranging from 0.002 U/mL to 0.005 U/mL per lxlO 6 DCs at 37 ⁇ C and an optimal desialytation time of 45 minutes.
- sialidase treated DC showed a 50 ⁇ 26 % decrease in binding of Sambucus nigra lectin (SNA), a lectin that recognizes mainly sialic acid a2,6-linked to lactosamine (6' sialyl Gal 1,4- GlcNAc), and a 45 ⁇ 10 % decrease in binding of Maackia amurensis lectin (MAA), a lectin that recognizes mainly sialic acid a2,3-linked to lactosamine (3' sialyl Gal 1,4-GlcNAc) or, linked to the Gal 1,3-GalNAc dissacharide (Figure 2A).
- SNA Sambucus nigra lectin
- MAA Maackia amurensis lectin
- the treatment with sialidase can be applied to human, murine and splenic DC, obtained as described in Examples 2 and 6, resulting in efficient reduction of sialic acid content at cell surface ( Figures 7A and 15A).
- the antigen upload of sialidase treated DC was carried out as follows: DC to be used in vaccination protocols for cancer therapeutics, as well as immune or infection diseases, need to be uploaded with specific antigens.
- tumour antigens the term relates to any antigen expressed only by tumour cells or aberrantly expressed by tumour cells. It includes proteins that can be uptaken and processed by DC, being the derived peptides presented to cytotoxic and helper T cells via MHC class I or class II, respectively.
- whole tumour cell antigens include tumour cell lysates, used in vaccination procedures; examples of specific tumour antigens used in vaccination comprise the gplOO glycoprotein, used as full length protein or as peptides specific for HLA-A*02:01.
- the sialidase treated DC can be uploaded with different types of antigens, as mentioned in the Examples 5, 6 and 7.
- DC are incubated with the antigens in cell culture medium, for 3 to 4 hours, at 37 Q C and 5% CO2.
- Cell ratio can be the equivalent of antigens from 1 tumour cell or more per each 5 DCs.
- antigen can be washed or maintained in culture.
- DC can be immediately co-cultured with the T cells or further activated with cytokines, such as TNF-a.
- the capacity of DC to phagocytose is preserved after sialidase treatment. No significant differences between sialidase treated and untreated DC, was observed regarding the endocytosis of whole tumour cell antigens ( Figure 2B). Therefore, the present composition does not affect antigen phagocytosis.
- the fact that the endocytic capacity of DC was not affected after sialidase treatment was unexpected because sialidase treatment induces maturation of DC and it is generally accepted that DC when mature decrease their ability to endocytose.
- the fact that maturation is associated with decreased endocytosis ability explains why all the other existing protocols for DC loading with tumour antigen are performed before maturation stimuli.
- sialidase treated DC showed an enhanced antigen presentation capacity and higher levels of co-stimulatory molecules.
- antigen loaded DC to be used in vaccination protocols need to show a mature phenotype which includes higher levels of M HC class I and class II antigen presenting molecules (signal 1) and the expression of co-stimulatory molecules, such as CD86 and CD40 (signal 2).
- sialidase treated DC that were loaded with antigen, show a higher maturation and co-stimulation profile (Figure 3and 11).
- tumour cell lysates as an example of whole tumour cell antigen (Example 5)
- the combination of sialidase treatment with antigen upload leads to an increase in the expression of other co-stimulatory molecules such as CD40 (1.1 fold), CD80 (1.5 fold), CD83 (1.5 fold) and the expression of the chemokine receptor CC 7 (1.2 fold), when compared with untreated DC, based on the flow cytometric analysis of cells stained with appropriate antibodies.
- co-stimulatory molecules such as CD40 (1.1 fold), CD80 (1.5 fold), CD83 (1.5 fold) and the expression of the chemokine receptor CC 7 (1.2 fold)
- the expression of these co-stimulatory markers as well as the chemokine receptor guarantee that sialidase treatment generates DC with co-stimulatory activity and that are able to migrate to lymph nodes in response to chemokine gradients.
- the sialidase treated DC show enhanced expression of Thl-inducing cytokines.
- the functional maturation of DC is also evaluated by the type and amount of cytokines expressed by these cells.
- tumour cell lysates as an example of whole tumour cell antigen (Example 5)
- antigen loaded DC showed a significant higher secretion of IL-12 cytokine, (4914,83 ⁇ 1039,63 preferably 4481 ⁇ 869.9), when compared to non sialidase treated DC (2674 ⁇ 46,25, preferably 1823 ⁇ 402.7).
- sialidase treatment increased 1.8 fold, preferably - 2.5 fold the expression of IL-12.
- the sialidase treated DC showed no significant increase in secretion of IL-6, and TNF-a showing that apart from IL-12, which has a pro-inflammatory and prominent role in the activation of anti-tumour response, there is not excessive pro-inflammatory cytokines release (Figure 3B and 11B).
- the sialidase effect was also observed in DCs generated from monocytes isolated from cord blood, which are tendentiously tolerogenic. These DCs were generated as described in Example 1, and treated with sialidase as described in Example 2. The effect of sialidase on the expression of antigen presenting molecule M HC-I and M HC II and co-stimulatory molecule CD86 was evaluated, by staining cells with appropriate antibodies, followed by flow cytometry analysis (as described in Example 1), 24 hours after the treatment.
- the secretion of pro-inflammatory cytokines of the sialidase treated DCs derived from cord blood monocytes precursors was evaluated by ELISA, as described in Example 10.
- the sialidase treatment of the DCs increased 3.9-fold the IL- 12 secretion, in comparison with untreated DCs.
- the sialidase treatment increased 1.5 fold the TNF-a secretion (Table I).
- the secretion of IL-6 and IL-10 was relatively low in cord blood monocyte- derived DCs and showed no significant alteration upon sialidase treatment.
- low levels of IL-6 together with increased levels of other pro-inflammatory cytokines such as IL-12 are recommendable for vaccination settings, to avoid excessive pro-carcinogenic inflammation.
- Table I Effect of sialidase treatment on the expression of antigen presentation (M HC-I e MHC-II) and co-stimulatory molecules (CD86) and the cytokines IL-12 and TNF-a by cord blood monocyte-derived DCs.
- sialidase treatment increases DC ability to activate T cells, in a whole tumour cell antigen model.
- the T cell activation is measured in different ways, including cell proliferation and cytokine expression.
- desialylated DC loaded with whole cell tumour antigens, provided by cancer cells lysates showed a 9.5-fold higher ability to induce proliferation of autologous T cells (59.42 ⁇ 8.53 % of proliferated T cells); while, the presence of T cells stimulated by untreated MoDCs loaded with tumour cell lysates resulted in a 4.9-fold increase of proliferation capacity (42.78 ⁇ 6.43 % proliferated T cells), as compared to unstimulated T cells.
- sialidase treatment led to a 1.4 -fold increase in the percentage of proliferative T cells ( Figures 4A and 12A).
- TNF-a and IFN- ⁇ are two Thl-inducing cytokines that synergize to induce anti-tumour immune responses.
- the expression of IL-10 and IL-4 is not induced showing that Th2-inducing cytokines are not stimulated.
- the MoDCs derived from cord blood, obtained as in Example 1 were tested for their capacity to activate T cells, after sialidase treatment. T cell proliferation was evaluated, in a Mixed Leukocyte Reaction, by CFSE dilution method as described in Example 3. The Cord Blood MoDC were treated or not sialidase and co-incubated with T cells. T cell proliferation was assessed after 7 days. As shown in Figure 12C, desialylated cord blood monocyte-derived DCs induced higher T cell proliferation.
- the antitumor activity mediated by T cells is improved by sialidase treated DC.
- the antitumor activity is measured in co-cultures using activated T cells against tumour cells.
- the cytotoxicity against tumour cells can be inferred by analysis of tumour cell viability or by measuring the release of CD107a (also called lysosomal-associated membrane protein-1 (LAMP-1)), which reflects the exocytosis of lytic granules from T cells.
- CD107a also called lysosomal-associated membrane protein-1 (LAMP-1)
- the effector cells are CD3 + T cells that had been instructed by DC loaded with tumour lysates and treated or not with sialidase as in Example 2.
- the cytotoxicity of T cells against tumour cells was considered based on the loss of GFP fluorescence by tumour cells, when become apoptotic. Loss of tumour cell viability was also measured based on tumour cells reactivity with 7AAD and annexin V. [0139] In an embodiment, the cytotoxicity against tumour cell was evaluated based on the release of cytotoxic granules from T cells, by evaluating CD107a expression.
- the viability of the tumour cell line MCF- 7, that stably express GFP was evaluated.
- GFP is a dye whose fluorescence is pH sensitive, decreasing significantly when the pH of the cell cytoplasm decreases, as it is the case of cells that initiate apoptosis.
- the intensity of the fluorescence of the GFP, in GFP-expressing tumour cells allows to infer which tumour cells survive or initiate apoptosis.
- tumour cell viability As shown in Figures 5 B and 13A co- culturing tumour cells with T cells stimulated with MoDC treated with sialidase and loaded with tumour cell lysates, the percentage of surviving tumour cells decreases to 66.50 ⁇ 5.73 % (i.e. reduce tumour cell viability up to 34%): this shows that sialidase treatment of MODCs leads to a better cytotoxic effect of T cells against the tumour cells than T cells previously stimulated with MoDC loaded with tumour cell lysates only, which showed a tumour cell survival of 77.53 ⁇ 7.77 %.
- Figure 13B we evaluated tumour cell viability based on the annexin V and 7-AAD staining.
- Tumour cell apoptosis was significantly increased when cells were incubated with T cells that had been previously primed with desialylated MoDCs loaded with tumour-antigens (MoDC Sia+TL ;37.95 ⁇ 1.83 %), compared to those incubated with T cells primed with fully sialylated MoDCs (MoDC TL ;32.03 ⁇ 2.47 %).
- these two methods of evaluating cytotoxicity against tumour cells show similar results and led to conclude that T cell dependent tumour killing is 20% improved by activation with the desialylated De composition.
- sialidase treatment improves DCs capacity to activate proliferation of helper T cell subpopulation.
- helper (CD4 + ) T cells is very important in the setting of antitumor immune responses.
- the role of CD4 + helper T cells in this response is largely attributed to providing regulatory signals required for the priming of antigen specific CD8 + cytotoxic T cells.
- the sialidase treatment improves DCs capacity to activate gplOO tumour antigen specific T cells and promotes cross-presentation.
- the activation of antigen specific cytotoxic T cells is extremely relevant for anti-tumour therapy.
- DCs were loaded with gplOO derived peptides according to Example 7: the gplOO long peptide (YLEPGPVTAN QLYPEWTEAQ LDC) is the SEQ ID 1 and the gplOO short peptide (YLEPGPVTA) is the SEQ ID 2.
- the aminoacid sequence that is shown underlined binds to HLA-A*0201, an allele of MHC class I. Both peptides are presented to CD8 + , cytotoxic T cells. The long peptide has to be internalized, conducted into phagossomes and be processed before it undergoes cross-presentation. The short peptide has a high affinity and binds directly to M HC-I, in particular to HLA-A*02:01, at cell surface, without previous endocytosis and processing.
- the data shows that sialidase treatment improves the capacity of DCs to activate gplOO tumour antigen specific T cells and promotes cross-presentation of antigens.
- Cross-presentation is an essential mechanism for eliciting anti-tumour response because it allows DC to present external antigens that were phagocytosed, through M HC class I molecules, and thus activating antigen-specific cytotoxic T cells.
- the sialidase treatment improves MHC class I stability ( Figures 14C, 14D e 14E).
- the efficient presentation of peptide-MHC class I complexes to CD8 + , cytotoxic T cells benefits from a stable peptide-MHC-l interaction.
- a T2 cell line that expresses unstable HLA-A*0201 was used to assess the effect of sialidase treatment in the stabilization of a gplOO and CMV pp65 peptides into the HLA-A*0201, as described in Example 8.
- the sialidase treatment of the T2 cell line resulted in an increased stability of the MHC-I HLA-A*0201 expression in the presence of the peptides ( Figures 14C and 14D) demonstrating that sialidase treatment is able to improve between 23 and 52% peptide-MHC class I stability in the presence of gplOO peptide and from 121% to 256% in the presence of CMV pp65 peptide.
- the MHC class I stability was also 34% improved by sialidase treatment even in the absence of peptide, suggesting that sialidase treatment can improve MHC class I stability in a peptide independent manner ( Figures 14C and 14D).
- Non sialidase treated cells decreased the M HC-I expression to approximately 46% (a decay of 54%) after 3 hours in the presence of brefeldin A. These results show that stability of the M HC-I molecule at the cell surface is significantly increase (Figure 14E).
- the sialidase treatment improves DC maturation using ovalbumin as model antigen.
- ovalbumin as a model antigen and murine splenic DC (sDCs) (Example 6).
- the DCs treated with sialidase as in Example 2 and pulsed with ovalbumin (OVA) show reduced SNA and MAA lectin binding and increased PNA binding ( Figures 7A and 15A), demonstrating the effectiveness of sialidase treatment.
- the sialidase treatment increased 23% the expression of MHC class I (from 15.3 ⁇ 0.5 to 18.9 ⁇ 0.7, MFI ⁇ SEM ), 46% the expression of class II (from 236.8 ⁇ 1.6 to 345 ⁇ 2.9, MFI ⁇ SEM ), as well as 121% the expression of the co-stimulatory molecule CD86 (from 8.9 ⁇ 0.6 to 19.7 ⁇ 4.3, M FI ⁇ SEM) ( Figure 15B), as compared to untreated sDCs.
- the sialidase treatment improves DC ability to activate T cells using ovalbumin as model antigen.
- the ability of murine DC, loaded with ovalbumin antigens, to activate helper or cytotoxic T cell responses is evaluated by using respectively transgenic OT-I (CD8 + ) or OT-II (CD4 + ) T cells, expressing ! cell receptors (TCRs) specific for ovalbumin peptides, in the context of either M HC class I or class II.
- sDC were loaded with OVA as in Example 6, and treated with sialidase as in Example 2 or left untreated and co- cultured with splenocytes isolated from OT-I or OT-II transgenic mice.
- the T cell activation was evaluated with a proliferation assay as in Example 3 and cytokine secretion as in Example 10.
- helper T cells CD4 + T cells
- splenocytes from OT-II mice.
- sialidase treated OVA-loaded sDCs 50.68 ⁇ 3.50 of CFSE low cells were found to significantly increase OVA-specific CD4 + T cell proliferation (6.9-fold increase) ( Figures 8A and 16 A).
- sialidase treated OVA-loaded sDCs significantly increase activation of CD4 + T cells based on the increased percentage of CD69 + and CD44 hi phenotype (21.50 ⁇ 1.450 vs 18.40 ⁇ 1.411% of CD69 + CD44 hi cells; Figures 8A and 16A).
- the levels of IFN- ⁇ , IL-6 and TNF-a in supernatants from the above-mentioned co-cultures were also evaluated by ELISA technique ( Figure 8B and Figures 16A and 16B).
- the TNF-a production was up-regulated 60% in the co-culture of OT-II splenocytes plus sialidase treated OVA-pulsed DCs (228.9 ⁇ 22.36 pg/ml) compared to the untreated ones (143.5 ⁇ 25.48 pg/ml).
- Pro-inflammatory cytokines IL-6 and IFN- ⁇ production was also upregulated 154% (from 170.7 ⁇ 26.46 to 67.24 ⁇ 33.64 pg/ml) and 97% (from 730.0 ⁇ 86.45 to 370.6 ⁇ 102.7 pg/ml), respectively.
- OVA-specific CD8 + T cells were assessed. As shown in Figures 8A and 16B, OVA-loaded sDCs strongly induced OT-I proliferation, which was 11% potentiated by sialidase treatment of sDCs (23.47 ⁇ 2.439 % of CFSE low cells) when compared to untreated sDCs (21.23 ⁇ 4.288 of CFSE low cells).
- sialidase treated OVA-loaded sDCs significantly increase activation of CD8 + T cells (10.09 ⁇ 0.2583 vs 8.320 ⁇ 0.4136%), based on the increased percentage of CD69 + and CD44 hi phenotype ( Figures 8A andl6B).
- the levels of IFN- ⁇ , IL-6 and TNF-a in supernatants from the OT-I co-cultures were also evaluated by ELISA technique ( Figures 8B and 16B). However, no significant changes in cytokine production were detected among the conditions analysed, as it is observable on Figures 8B and 16B.
- the sialidase treatment improves DC ability to induce antigen-specific killing of tumour cells, using ovalbumin as model antigen.
- mouse melanoma cell line B16-OVA that stably expresses OVA (H2b) as described in Example 9 was used.
- splenocytes that were incubated with non-OVA pulsed DC were used.
- the B16-OVA tumour cells that were incubated with the negative controls showed a cell viability of more than 80% (not shown) compared to the ones that were stimulated with OVA-pulsed DC, for all conditions (Figure 8C and Figures 9A and 9B).
- the percentages of B16-OVA cell viability was significantly lower following exposure to splenocytes activated with sialidase treated OVA-pulsed DC, compared to the splenocytes activated with untreated OVA-pulsed DC.
- the sialidase treatment improves OVA peptide antigen specific presentation through MCH class I.
- the antigen specific presentation through MCH class I is essential to enable DC to activate antigen specific T cells.
- One of the tools to address this question consists in using murine DC loaded with the ovalbumin antigen.
- the presentation of the ovalbumin-derived peptide SIINFEKL through M HC class I is easily accessed by flow cytometry using the 25-D1.16 monoclonal antibody.
- the DCs treated with sialidase and loaded with OVA showed a 1.5-fold increase in the M HC-l-dependent antigen presentation ability after sialidase treatment (Figure 9C).
- DC isolated directly from blood or other tissue can also be used.
- Human monocytes can be isolated from peripheral blood (PB) withdrawn from adult individuals or from cord blood (CB).
- PB peripheral blood
- CB cord blood
- Peripheral blood can be, for example, obtained from blood donations, of healthy individuals, while CB can be obtained, for example, from a CB bank.
- PB and CB can be freshly processed or cryopreserved, for example, at -150°C.
- Added cryoprotectant agents can be 10% of dimethyl sulfoxide (DMSO), added drop-by-drop.
- DMSO dimethyl sulfoxide
- Cryopreserved cells can be unfrozen by, for example, a quick thawing (for approximately 1 minute) in a 37°C water bath, then suspending and mixing the cells with an equal volume of cell culture medium supplemented with 20% fetal bovine serum (FBS). After collecting cells by centrifugation, red blood cells can be lysed.
- FBS fetal bovine serum
- mononuclear cells can be first isolated by, for example, density gradient centrifugations, using a Ficoll solution (Biochrom AG) in a 5:3 - 5:4 ratio, preferably a 5:3 ratio (blood dilution: Ficoll).
- Ficoll is a hydrophilic polysaccharide with 1.077 g/ml density, which is superior to PBMCs, but inferior to erythrocytes and granulocytes.
- blood is separated by a density gradient, allowing the formation of four layers (from bottom to top of the tube): i) erythrocytes and granulocytes layer; ii) Ficoll solution layer; iii) a thin mononuclear cells layer; iv) and then a large layer, corresponding to plasma and the majority of the platelets.
- the mononuclear cell layer is washed using, for example phosphate buffer solution (PBS) and centrifuging cells twice, at 4 Q C to improve removal of platelets.
- PBS phosphate buffer solution
- Monocytes can be isolated by, for instance, positive selection using magnetic beads conjugated to antibodies against CD14, a marker mainly expressed by monocytes. For example, incubating mononuclear cells with CD14 Microbeads (Miltenyi Biotec), for 15 minutes, in the presence of beads buffer (PBS with 0.5% bovine serum albumin and 2 mM ethylenediamine tetraacetic acid (EDTA)). Cells are then loaded to a magnetic field of a MidiMACS Separator (Miltenyi Biotec) which will retain the cells labeled with the Microbeads (CD14 + cells or monocytes). Many commercially available media can be used to culture monocytes.
- such media include: RPM I-1640 media with 10% FBS, 2 mM glutamax supplement with 100 ⁇ g/mL penicillin/streptomycin, 1% non-essential amino acids, 1% sodium pyruvate.
- the culture media for monocytes is supplemented with recombinant human (rh)IL-4 and rhGM-CSF for example, with 750 U/mL of IL-4 and 1000 U/mL of GM-CSF, and cultured at 37 Q C, in a humidified atmosphere with 5% CO2.
- the cells are cultured, for example, at lxlO 6 cells/mL and half the media is replaced with fresh one every two days, during 5-7 days.
- monocyte derived DC is confirmed by flow cytometry analysis, using markers for DC, for example CDlc or CDla and the M HC class II molecules, the HLA-DR, as exemplified in Figure lA and IB.
- Maturation of DC is crucial for the production of anti-tumour vaccines.
- culture medium can be supplemented with inflammatory cytokines, for example, recombinant human TNF-a, IFN- ⁇ ; and or bacterial components such as lipopolysaccharide, or viral double strand RNA such polyl:C and cultured at 37 Q C, in a humidified atmosphere with 5% CC for 24h to 48h.
- the maturation of DC is confirmed by flow cytometry analysis, by evaluation of the expression of maturation markers for example MHC class II molecules, CD86, CD40, CD80 as exemplified in Figures 3A and 11A.
- Physiological maturation of DC is also evaluated by the expression of cytokines by ELISA as exemplified in Figures 3B and 11B.
- the sialidase is used for its enzymatic activity against a.2,3-, a.2,6- or a2,8- linked sialic acids.
- DC are desialylated using a recombinant sialidase, at a concentration ranging from 0.025U/mL to 0.1 U/mL, from 45 minutes to overnight, at 37 Q C. Control experiments are performed in parallel with heat-inactivated sialidase.
- the desialylation of DC i.e.
- the efficiency of the sialidase treatment can be confirmed, for example, by staining with fluorescent lectins: fluorescein isothicyanate (FITC)-labeled Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAA) and Peanut agglutinin lectin (PNA) and analysed by flow cytometry.
- fluorescent lectins fluorescein isothicyanate (FITC)-labeled Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAA) and Peanut agglutinin lectin (PNA)
- SNA is a lectin which recognizes mainly sialic acid a2,6-linked to lactosamine (6' sialyl Gal 1,4-GlcNAc);
- MAA is a lectin that recognizes mainly sialic acid a2,3-linked to lactosamine (3' sialyl Gal 1,4-GlcNAc) or, linked to Gal 1,3-GalNAc dissacharide
- PNA is a lectin specific for the non-sialylated O-linked chains (Gal 1,3-GalNAc, also known as T antigen).
- the degree of desialylation can be quantifiable based on the ratio of the mean fluorescence intensity (M Fl) of DC after sialidase treatment compared to non-treated DC.
- Sialidase treatment leads to decreased SNA and MAA binding and increased PNA reactivity ( Figure 2A).
- Sialidase treatment can be stopped by ressuspending cells in complete media containing FBS or by diluting the sialidase reaction volume 10 times with PMI medium.
- T cells refer to a population of hematopoietic derived white blood cells, characterized by the expression of T cell receptors (TCRs), as well as the CD3 co-receptor. These cells also express CD4 and CD8 surface proteins associated with ⁇ T cell receptors, which characterize, respectively, helper and cytotoxic T cells. Helper T cells express several cytokines that are important for the activity of several other immune cells, including cytotoxic T cells. Cytotoxic T cells have the potential to kill cancer cells, cells that are infected (particularly with viruses), or cells that are damaged in other ways. Each T cell is specific for a given antigen presented via MHC by antigen presenting cells, such as DC.
- T cells can be obtained from PB, CB or other biological sources or alternatively, a human T cell line can be used.
- the T cell population can be, for example, the autologous CD14 " fraction obtained during monocyte isolation, which comprehends 75% of T cells.
- the T cell population or its subpopulations can be further enriched by, for example, positive selection using magnetic beads conjugated to antibodies, such as MicroBeads (Miltenyi Biotec), against CD3, CD4 or CD8.
- the T cells population or subpopulations can also be enriched by, for example, negative selection, using magnetic beads, conjugated to a cocktail of antibodies against every white blood cells except the desired population.
- T cell proliferation can be measured for example by using the method of carboxyfluorescein succinimidly ester (CFSE) dilution, which relies on the dilution of a fluorescent dye from parental cells to daughter cells.
- CFSE carboxyfluorescein succinimidly ester
- T cells are resuspended at 50 x 10 6 /mL and labelled with 10 ⁇ of CFSE solution, for 5 minutes at room temperature, in the dark. After washing, labelled cells are distributed in a 96 well U- bottom plate already containing or not the stimulator cells that can be mature DC. The ratio of DC:T can be 1:2 until 1:100.
- the T cells are incubated at 37 Q C, and the CFSE intensity is evaluated at different times.
- rhlL-2 (10 lUg/mL) may be added at day 1, to help T cell division. The percentage of proliferative T cells is calculated based on the percentage of population that shows reduced CFSE expression by at least one cell division.
- T proliferation can also be assessed by [ 3 H]-thymidine incorporation into newly synthesized DNA molecules. After co-incubation of MoDCs with T cells for 3 days, [ 3 H]-thymidine solution is added to the co-culture. After 24 h, cells are harvested into filters and [ 3 H]-thymidine incorporation is assessed using scintillation counter that allow measuring the incorporation of radioactive thymidine into DNA of proliferating T cells.
- Cells are routinely counted, for example, by visualization at the optic microscope, and the viability can be assessed by trypan blue staining exclusion, using a Neubauer chamber. Trypan blue is used for example at 0.4% to discriminate dead cells (cells with blue coloration).
- Other cell viability exclusion stains can be used, such as the 7-Aminoactinomycin D (7AAD) (Sigma) or Live/dead fixable stain kit (Molecular Probes) that are used to identify dead cells, and annexin V that can be used to stain apoptotic cells, all of which are evaluable by flow cytometry.
- tumour cell apoptosis may also be determined, based on the acidification of their cytoplasm.
- This acidification can be measured by using a reporter fluorescence, such as for example, in GFP-expressing tumour cells, whose GFP intensity decrease or is completely lost according to the acidification of the cell cytoplasm.
- a reporter fluorescence such as for example, in GFP-expressing tumour cells, whose GFP intensity decrease or is completely lost according to the acidification of the cell cytoplasm.
- Example 5 Testing efficacy of desialylated DC, using tumour cell lysates as a whole cell antigen model
- the tumour antigens are from whole cells and obtained by lysing the cells (tumour cell lysates).
- Patient-derived cancer cells or available cell lines can be used to generate cell lysates, for example, the MCF-7 cell line, originally isolated from a pleural effusion of a 69-year-old Caucasian woman with a diagnosis of invasive breast ductal carcinoma (Soule et al., 1973).
- MCF-7 cells express HLA-A*02:01, an HLA allele abundant in population. Therefore, this cell line functions as a target of T cells of HLA- A*02:01 individuals.
- the cell lines can be labelled fluorescent, for example, the MCF-7 breast cancer cells stably expressing the green fluorescent protein (MCF-7-GFP) (Cell Biolabs).
- MCF-7-GFP green fluorescent protein
- Many commercially available media can be used to culture cancer cell lines.
- such media include: DM EM medium, supplemented with 10% FBS, 2mM L-Glutamine and 100 ⁇ g/mL penicillin/ streptomycin.
- Cells can be lysed, for example, through four freeze-thaw cycles, at -80 Q C and 37 Q C, respectively. Cell lysates are centrifuged to remove cell debris and the supernatants are stored at -80 Q C.
- the cell lysis is confirmed, for example, at the optic microscope, by using trypan blue dye exclusion and by culturing an aliquot of lysate in complete culture medium during 2 days, to detect eventual cell growth.
- the concentration of protein in the tumour cell lysates is for example, 1 mg/mL.
- DC can be, for example, incubated with antigens in complete PMI medium, for 3 to 4 hours, at 37 Q C and 5% CO2.
- Cell ratio can be the equivalent of 1 or more tumour cells per each 5 DC.
- antigen can be washed or maintained in culture.
- DCs can be immediately co-cultured with the T cells or further activated with cytokines, such as TNF-a.
- Example 6 Testing efficacy of desialylated DC using ovalbumin (OVA) as a model antigen
- the ovalbumin is used as a model antigen to load murine DC (sDCs) and to be presented to genetically modified T cells.
- T cells are from C57BL/6 transgenic mice, expressing OVA-specific, M HC class I and MHC class II restricted TCRs, named B6.0T-I and B6.0T-II (respectively). Mice can be 6-8 weeks old, age and sex matched and sacrificed by, for example, carbon dioxide inhalation followed by cervical dislocation.
- Murine sDCs can be obtained by CDllc + cell enrichment and incubated with OVA, for 3 to 6 hours at 37 Q C in a humidified atmosphere with 5% CO2.
- Murine T cells are isolated for example, from animal spleens by mechanical disruption, followed by erythrocytes lysis. Splenocytes, from B6.0T-I and B6.0T-II mice, are resuspended, for example, at final concentration of 1 x 10 7 /mL of media. T cell proliferation is estimated, for example, by the method of CFSE dilution as mentioned above.
- Tumour antigen for DCs loading can be a peptide derived from a tumour-associated protein.
- the peptide is screened for binding to specific MHC molecule, thus guarantying that it will be presented to peptide-specific T cells.
- the tumour antigen is a peptide derived from the gplOO protein, a known melanoma antigen.
- two gplOO peptides can be used: gplOO short peptide (YLEPGPVTA) and gplOO long peptide (YLEPGPVTANRQLYPEWTEAQRLDC).
- the aminoacid sequence that is shown underlined binds to HLA-A*0201, an allele of M HC class I, frequent in population.
- the short peptide is internalized, directed into cytoplasm, transported into the endoplasmic reticulum (ER), and loaded on MHC class I molecules without being processed; then the peptide-M HC-l complex is further transported to the plasma membrane to be recognized by CD8 + cytotoxic T cells.
- the gplOO long peptide is internalized through phagocytosis and after processing it is cleaved.
- DC can be incubated with different concentrations of gplOO peptide, for example, 1 to 30 ⁇ in RPM I medium, for 3 to 4 hours, at 37 Q C and 5% CO2. After incubation with antigens, DC are co- cultured with gplOO-specific CD8 + T cell clones in IMDM medium. T cell clones activation can be evaluated, for example, by measuring the secretion of IFN- ⁇ cytokine by ELISA, after overnight or 3 days incubation.
- T2 cell line (mutant LCL ⁇ T-lymphoblastoid hybrid cell line, 174 ⁇ CEM.T2) is used.
- T2 cells have a transporter associated with antigen transport (TAP) mutation that causes a peptide supply defect, i.e., they cannot incorporate peptides into MHC molecules.
- T2 cells express stable M HC-I (HLA-A*02:01) molecules on their surface when an exogenous peptide is provided.
- Peptide binding assays can be performed by, for example, incubation of T2 cells, pre-treated or not with sialidase, with different concentrations of gplOO or CMVpp65 peptides in the presence of ⁇ -microglobulin for 3 to 4 hours, at 37 °C. After incubation, T2 cells are washed and stained with anti-HLA-A*02 antibodies and analysed by flow cytometry.
- T2 cells can be treated or not with sialidase in the presence of brefeldin A (BFA).
- BFA brefeldin A
- BFA brefeldin A blocks protein transport from the endoplasmic reticulum to the Golgi network, therefore suppressing the incorporation of newly synthesized proteins into the cell membrane.
- T2 cells were treated or not treated with sialidase in the presence of BFA. After treatment, sialidase was washed out but BFA remained in the culture medium. At different time points up to 4 hours after treatment, T2 cells are washed and stained with anti-HLA-A*02 antibodies and analysed by flow cytometry.
- the cytotoxic capacity of T cells is evaluated using T cells boosted with autologous DC that have been subjected to different treatments.
- the cell ratio can be, for example, 1 DC per 5 T cells, and the incubation time of 7 to 21 days, with periodic reloads with DC submitted to specific treatments.
- T cells can be activated by addition of cytokines, for example, rhlL-7 (5 ng/mL).
- the proliferation of T cells can be stimulated by supplementation with rlL-2 (lOUI/mL).
- Activated T cells are then cultured against target tumour cells that can be patient-derived cancer cells or commercially available cell lines.
- the MCF-7-GFP cell line can be pre-cultured in 96 well flat-bottom plates, for at least 4 h, at 37 Q C.
- the cell ratio can be, for example, 10 or less T cells per each tumour cell. Co-cultures take place for 5 to 24 hours.
- the cell killing is evaluated by different strategies.
- tumour cell viability is estimated as mentioned in Example 4.
- tumour and T cells can be co-cultured in the presence of the anti-CD107a antibody during 1 hour, at 37 Q C. Then brefeldin A is added to the co-culture to block protein secretion, followed by incubation for 4 hours at 37 Q C. After this period, the expression of the CD107a molecules can be evaluated by flow cytometry.
- the mouse melanoma cell line B16-OVA was used as target cells and stained with CFSE, as described in Example3. Subsequently, the CFSE-labelled cells were seeded into 96-well microplates at a concentration of 0.1 x 10 6 cell/well and incubated at 37 Q C in 5% CO2 incubator for 4 hours. The splenocytes from OT-I and OT-II mice were added to the microplates at a ratio of 5:1 (splenocytes: tumour cells) and cultured for 24 hours at 37°C and 5% CO2.
- Splenocytes from OT-I and OT-II mice were activated previously by incubation for 72 hours with OVA pulsed and non-pulsed mouse CDllc + cells treated with sialidase or left untreated. After 24 hours, tumour cell killing is evaluated, as mentioned in Example 4.
- cytokine expression For the quantification of cytokine expression, culture supernatants were collected before cell harvest and frozen at -20°C. Concentrations of IL-4, IL-6, IL-10, IFN- ⁇ , TNF-a, IL-12, were quantified using ELISA technology as recommended by the manufacturer. Briefly, 96-well plates were coated with capture antibodies, overnight at 4 Q C and then blocked for 1 hour at room temperature with 1% BSA. Next, the supernatants and standard concentrations of cytokines were incubated in duplicates or triplicates for 2 hours, at room temperature and washed 4 times with PBS-0.05%tween.
- biotinylated detection antibodies were then added and incubated for 2 hours at room temperature, followed by 4 washes and horseradish peroxidase-conjugated-streptavidin incubation for 20 minutes. After 4 washes, plates were incubated with tetramethylbenzidine substrate in the dark and the reaction stopped by addition of 1M HCL. Bound complexes were then detected by A450 measurement on a plate reader and cytokine concentration was calculated as pg/ml using the standard curves.
- fold increase represents the ratio between value obtained for sialidase treatment condition and the corresponding value without sialidase treatment.
- Fold decrease represents the ratio between the value without sialidase treatment and the value obtained for sialidase treatment condition. For example, a 2 fold increase represents a 100% increase, and a 2 fold decrease represents a 50% decrease.
- a fold change is a measure of how much a quantity changes going from an initial value to a final value in comparison to a control value. Therefore, a fold change is a ratio.
- the disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
- the disclosure also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT10862115 | 2015-06-30 | ||
PCT/IB2016/053901 WO2017002045A1 (en) | 2015-06-30 | 2016-06-29 | A viable cell population, method for production and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3317402A1 true EP3317402A1 (de) | 2018-05-09 |
EP3317402B1 EP3317402B1 (de) | 2024-02-14 |
EP3317402C0 EP3317402C0 (de) | 2024-02-14 |
Family
ID=56507625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16741685.8A Active EP3317402B1 (de) | 2015-06-30 | 2016-06-29 | Lebensfähige zellpopulation, verfahren zur herstellung und verwendungen davon |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3317402B1 (de) |
BR (1) | BR112018000027A2 (de) |
WO (1) | WO2017002045A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3906096A4 (de) * | 2019-01-03 | 2023-03-01 | Palleon Pharmaceuticals Inc. | Verfahren und zusammensetzungen zur behandlung von krebs mit immunzellen |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2766299T3 (es) | 2001-09-06 | 2020-06-12 | Northwest Biotherapeutics Inc | Composiciones y procedimientos para la activación linfocitaria de células dendríticas monocíticas y células T para generar una respuesta Th-1 |
US20050003533A1 (en) | 2003-05-08 | 2005-01-06 | Pawel Kalinski | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |
EP1840206A1 (de) | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Kompositionen für die Vorbereitung reifer dendritische Zellen |
EP3336174A1 (de) | 2006-06-02 | 2018-06-20 | Robert Sackstein | Zusammensetzungen und verfahren zur modifizierung der zelloberflächenglycane |
JP2011136964A (ja) | 2009-12-28 | 2011-07-14 | Gifu Univ | ノイラミン酸誘導体、シアリダーゼ活性阻害剤及び抗インフルエンザ薬 |
TR201802987T4 (tr) | 2010-02-03 | 2018-03-21 | Dsm Ip Assets Bv | Süt teknolojisinde siyalidaz kullanımı. |
EP2709446A2 (de) | 2011-05-17 | 2014-03-26 | Velico Medical, Inc. | Blutplättchenaufbewahrung unter verwendung eines sialidase inhibitors |
-
2016
- 2016-06-29 EP EP16741685.8A patent/EP3317402B1/de active Active
- 2016-06-29 BR BR112018000027A patent/BR112018000027A2/pt unknown
- 2016-06-29 WO PCT/IB2016/053901 patent/WO2017002045A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP3317402B1 (de) | 2024-02-14 |
EP3317402C0 (de) | 2024-02-14 |
WO2017002045A1 (en) | 2017-01-05 |
BR112018000027A2 (pt) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thurner et al. | Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | |
Feuerstein et al. | A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use | |
Norbury et al. | Constitutive macropinocytosis allows TAP‐dependent major histocompatibility compex class I presentation of exogenous soluble antigen by bone marrow‐derived dendritic cells | |
US9211321B2 (en) | Method for proliferation of antigen-specific T cells | |
KR101527260B1 (ko) | 수상세포의 제조방법 | |
Ferlazzo et al. | Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates | |
Kitawaki et al. | Cross-priming of CD8+ T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia | |
KR20180049169A (ko) | 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법 | |
WO2006120439A2 (en) | Cellular vaccine and use thereof | |
US20150166955A1 (en) | Method for loading of dendritic cells with class i antigens | |
Spisek et al. | Maturation of dendritic cells by bacterial immunomodulators | |
Von Euw et al. | Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes | |
Zhang et al. | Bone marrow-derived inflammatory and steady state DCs are different in both functions and survival | |
KR101568323B1 (ko) | 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법 | |
Truxova et al. | Day 3 Poly (I: C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs | |
Aloysius et al. | Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs | |
Jonuleit et al. | Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells | |
EP3317402B1 (de) | Lebensfähige zellpopulation, verfahren zur herstellung und verwendungen davon | |
Lehner et al. | Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions | |
Barron et al. | Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development | |
US9149515B2 (en) | Interferon-alpha-producing bone marrow dendritic cells | |
EP2097099A1 (de) | Neue zusammensetzungen und ihre verwendungen | |
Hildenbrand et al. | IFN-γ enhances TH1 polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions | |
US20210139852A1 (en) | Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use | |
Pi et al. | Generation of high cross-presentation ability human dendritic cells by combination of interleukin 4, interferon β and GM-CSF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180105 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190218 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230925 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSIDADE NOVA DE LISBOA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016085766 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20240311 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240614 |